{
  "pmcid": "12302991",
  "sha256": "b4f1da3cf70ed4fb27db24d5dd8eef24b5682b68cd8efe22d8b7d605066f8120",
  "timestamp_utc": "2025-11-09T22:21:00.363029+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.177810033104155,
    "reading_ease": 17.616967150496578,
    "word_count": 231
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "retrospective cohort study"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients who underwent open surgery for gynecologic malignancies using ERAS protocols from March 2016 to December 2018"
      },
      "Intervention": {
        "score": 1,
        "evidence": "Participants were divided into two cohorts based on the presence or absence of postoperative AKI within 30 days."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the development of long-term chronic kidney disease (CKD) and cardiac conditions postoperatively among patients who did and did not develop acute kidney injury (AKI) after open ERAS surgery for gynecologic malignancy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the 36-month cumulative incidence of CKD."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Among 378 patients, 51 (13.5%) developed postoperative AKI."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Over a median follow-up of 19.4 months, patients with AKI were twice as likely to develop CKD (p<0.001)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "On univariate analysis, AKI was associated with CKD (HR=2.17, 95% CI 1.22â€“3.84)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}